Meridian Bioscience (VIVO) Tops Q4 EPS by 4c, Revenue Beat; Offers FY19 EPS Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Meridian Bioscience (VIVO) Tops Q4 EPS by 4c, Revenue Beat; Offers FY19 EPS Guidance Below Consensus

Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Sets Fiscal 2019 Cash Dividend Rate, and Provides Fiscal 2019 Guidance

November 8, 2018 7:30 AM EST

CINCINNATI, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2018.

Business Highlights:

Completed consolidation of separately-run businesses into two integrated global business unitsStreamlined organization to build a stronger, more efficient and sustainable management structureEntered into a strategic collaboration with DiaSorin to sell Helicobacter Pylori testsLaunched new branding strategyReleased fiscal 2019 guidance of per share diluted earnings between $0.74 and $0.76 on net revenue growth of 2%-4% and operating margin of... More